These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17447409)

  • 1. My love with monoamine oxidase, iron and Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 2006; (71):V-IX. PubMed ID: 17447409
    [No Abstract]   [Full Text] [Related]  

  • 2. My fifty years (almost) of monoamine oxidase.
    Sandler M
    Neurotoxicology; 2004 Jan; 25(1-2):5-10. PubMed ID: 14697875
    [No Abstract]   [Full Text] [Related]  

  • 3. Rasagiline (Azilect) for Parkinson's disease.
    Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoamine oxidase and their inhibitors. Preface.
    Int Rev Neurobiol; 2011; 100():xi-xv. PubMed ID: 21971011
    [No Abstract]   [Full Text] [Related]  

  • 5. 90 years of monoamine oxidase: some progress and some confusion.
    Tipton KF
    J Neural Transm (Vienna); 2018 Nov; 125(11):1519-1551. PubMed ID: 29637260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine and Parkinson's disease. A personal view of the past, the present, and the future.
    Hornykiewicz O
    Adv Neurol; 2001; 86():1-11. PubMed ID: 11553966
    [No Abstract]   [Full Text] [Related]  

  • 8. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical overview of the WFN-organised Congresses on Parkinson's disease and related disorders.
    Battistin L; Korczyn AD; Wolters ECh
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S205-7. PubMed ID: 18267236
    [No Abstract]   [Full Text] [Related]  

  • 10. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xenobiotic enzyme profiles and Parkinson's disease.
    Williams A; Steventon G; Sturman S; Waring R
    Neurology; 1991 May; 41(5 Suppl 2):29-32; discussion 32-3. PubMed ID: 2041591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
    Chazot PL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.
    Pretorius J; Malan SF; Castagnoli N; Bergh JJ; Petzer JP
    Bioorg Med Chem; 2008 Sep; 16(18):8676-84. PubMed ID: 18723354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Rajeswari A; Sabesan M
    Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood catechol-O-methyltransferase activity in Parkinson's disease.
    Frère JM; Barbeau A
    Lancet; 1971 Jul; 2(7718):269-70. PubMed ID: 4104811
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoamine oxidase substrates in Parkinson's disease.
    Humfrey CD; Steventon GB; Sturman SG; Waring RH; Griffiths B; Williams AC
    Biochem Pharmacol; 1990 Dec; 40(11):2562-4. PubMed ID: 2268374
    [No Abstract]   [Full Text] [Related]  

  • 18. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors.
    López-Muñoz F; Alamo C; Juckel G; Assion HJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):555-9. PubMed ID: 18004120
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoamine oxidases--new vistas. Introduction and historical background.
    Blaschko H
    Adv Biochem Psychopharmacol; 1972; 5():1-10. PubMed ID: 4561510
    [No Abstract]   [Full Text] [Related]  

  • 20. Mary Bernheim and the discovery of monoamine oxidase.
    Slotkin TA
    Brain Res Bull; 1999; 50(5-6):373. PubMed ID: 10643441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.